Synthesis, characterization of new heterocyclic compound: pyrazolyl hydrazino quinoxaline derivative: 3-[5-(hydroxy1methyl)-1-phenylpyrazol-3-yl]-2-[2, 4, 5-trimethoxybenzylidine] hydrazonyl-quinoxaline of potent antimicrobial, antioxidant, antiviral, and antitumor activity

Abstract

Pyrazole and quinoxaline synthesis is gaining popularity due to its wide range of pharmacological qualities, including antiviral, antagonist, antibacterial, anticancer, anti-inflammatory, analgesic, anti-prostate cancer, herbicidal, acaricidal, and insecticidal effects. A novel and innovative heterocyclic biologically active compound, 3-[5-(hydroxy1methyl)-1-phenylpyrazol-3-yl]-2-[2, 4, 5-trimethoxybenzylidine] hydrazonyl-quinoxaline abbreviated as (TMPyrQu) is prepared by simple low-cost method. The chemical structure of the compound is assigned based on IR, 1H NMR, 13C NMR as well as elemental analysis. TMPyrQu showed potent antimicrobial activity: higher antibacterial activity against p. aeruginosa, E. coli, S. aureus, Streptomyces (inhibition zone (mm) 16, 14, 19, 18, 12), respectively, than the standard antibiotic ampicillin for bacteria with corresponding inhibition zone (mm) (12, 11, 9, 13).The antifungal activity of TMPyrQu is higher than ampicillin Fluconazole biocide (inhibition zone of 16 mm and 11 mm, respectively). It also demonstrated robust antiviral activity against the hepatitis B and good anticancer activity and cytotoxicity on the cell lines HepG-2 (liver carcinoma) and MCF-7 (breast carcinoma), with higher performance for breast cancer. The TMPyrQu molecule has the potential to be a powerful anticancer and immunosuppressive medication. TMPyrQu showed strong antioxidant activity that represented a first-line defense against free radical and reactive oxygen species (ROS), that target lipids, protein, and nucleic acid contributing to the progression of many chronic diseases. The novelty of this study is that it is the first time a multidisciplinary biologically active compound has been synthesized and evaluates its biological activity as well as its effectiveness against breast and liver tumor from a chemical, biochemical and medicinal perspective. The lack of adequate evaluation of such promising biocompatible biologically active compounds, despite the fact that the COVID-19 virus affects the entire world is the driving factor behind this work.